Dianthus Therapeutics (NASDAQ:DNTH) Releases Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Dianthus Therapeutics (NASDAQ:DNTH) posted its earnings results on Wednesday. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.13, FiscalAI reports. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. The business had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $0.46 million.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH traded up $3.11 on Wednesday, hitting $85.81. 1,679,417 shares of the stock traded hands, compared to its average volume of 948,135. The business’s fifty day moving average is $91.11 and its two-hundred day moving average is $85.18. Dianthus Therapeutics has a 12 month low of $32.42 and a 12 month high of $117.88. The firm has a market capitalization of $4.70 billion, a price-to-earnings ratio of -20.68 and a beta of 1.47.

Insider Transactions at Dianthus Therapeutics

In other news, Director Simon Read sold 2,778 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the transaction, the director directly owned 2,778 shares in the company, valued at approximately $326,553.90. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Anne McGeorge sold 7,750 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the transaction, the director owned 1,250 shares in the company, valued at $136,262.50. This trade represents a 86.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 242,429 shares of company stock valued at $26,118,913. 3.02% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Raymond James Financial reissued a “strong-buy” rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Wedbush lifted their target price on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Truist Financial upped their price target on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Citigroup assumed coverage on shares of Dianthus Therapeutics in a report on Friday, September 4th. They issued a “buy” rating and a $156.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $128.54.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.